Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Fmiso-PET is a non-invasive modality used for the assessment of tumour hypoxia, and increasingly for planning radiotherapy. However, the availability and contrast properties of Fmiso are not ideal. Recent efforts to compare FDG binding with that of Fmiso, in order to ascertain FDG's potential as a marker of hypoxia, have met with mixed results. The potential reasons for correlated and disparate binding patterns between the two tracers have been postulated, but not formally outlined as yet. We present a model of a key component of the image formation process - tracer pharmacokinetics. This involves a series of coupled PDEs, describing the interplay between concentrations of oxygen, glucose, HIF, Fmiso and FDG. We use this model to assess the general feasibility of FDG as a surrogate marker of hypoxia and find that its utility is dependent on activity of oncogenic pathways.


Conference paper

Publication Date



540 - 543


POSITRON EMISSION TOMOGRAPHY, PET, biomedical image processing, biological systems modeling